The company is focused on the clinical development and commercialisation through partnering of its highly innovative anti-infective portfolio and is actively seeking partners for the XF-73 Nasal programme and has an open door policy to discussing potential business relationships. These range from partnering and licensing through to investment and non-dilutive funding as well as risk sharing and joint ventures with industry, academia and governments.
Please contact us to start a discussion.